Sodium-glucose cotransporter type 2 inhibitors (SGLT2): From familial renal glycosuria to the treatment of type 2 diabetes mellitus;Inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2): De la glucosuria renal familiar al tratamiento de la diabetes mellitus tipo 2

Nefrologia

Volumn 30, Issue 6, 2010, Pages 618-625

  López, G Pérez ^a   Albarrán, O González ^a   Megías, M Cano ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Familial renal glucosuria; SGLT2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

2 (3 (4 ETHOXYBENZYL) 4 CHLOROPHENYL) 6 HYDROXYMETHYLTETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLUCOSE; GLUCOSIDE; PHLORIZIN; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2;

ABSORPTION; ANIMAL; DOG; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCONEOGENESIS; HOMEOSTASIS; HUMAN; KIDNEY; KIDNEY PROXIMAL TUBULE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL DIABETES; REVIEW;

ABSORPTION; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOGS; DOUBLE-BLIND METHOD; GLUCONEOGENESIS; GLUCOSE; GLUCOSIDES; GLYCOSURIA, RENAL; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY TUBULES, PROXIMAL; MICE; PHLORHIZIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 78649915745     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Sep.10494     Document Type: Review

References (29)

1. De Fronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes Care 2009;58:773-95.
2. DeFronzo RA, Abdul-Ghani M. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice. Endocr Pract 2008 Sep;14(6):782-90.
3. Noonan WT, Shaprio VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin induced diabetic rats. Life Sci 2001;68:2967-77.
4. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 1994;266:F283-F290.
5. Guyton AC, Hall JE. Urine formation and the kidneys. In Textbook of Medical Physiology. 9th ed. Philadelphia, Pa.: W.B. Saunders, 1996;332-5.
6. Wright EM. Renal Na-glucose transporters. Am J Physiol Renal Physiol 2001;280:F10-F18.
7. Butterfield WJH, Keen H, Whichelow MJ. Renal glucose threshold variations with age. BMJ 1967;4:505-7.
8. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephol 1997;8:943-8.
9. Mogensen CE. Maximum tubular reabsorpiton capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scan J Clin Lab Invest 1971;28:101-9.
10. Hediger MA, Rhoads DB. SGLT2 Mediates Glucose Reabsorption in the Kidney. Physiol Rev 1994;74:993-1026.
11. Bakris GL, Fonseca V, Sharma K, Wright E. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7.
12. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43.
13. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82.
14. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43.
15. Ganong WF. Review of Medical Physiology. 19th ed. Stamford, CT: Appleton & Lange, 1999;667-95.
16. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34.
17. White JR. Apple Trees to Sodium Glucose Co-Transporter Inhibitors. Clinical Diabetes 2010;28(1):5-10.
18. Abdul-Ghani MA. Inhibition of renal glucose absorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-90.
19. Isis Pharmaceuticals. Pipeline [article online]. Available from http://www.isispharm.com/Pipeline/index.htm.
20. Wancewicz EV, Siwkowski A, Meibohm B, et al. Long term safety and efficacy of ISIS-388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Diabetes 2008;57(Suppl 2):Abstract 334-OR.
21. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Pfister M. Dapgliflozin, a novel, selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6.
22. Brooks AM, Thacker SM. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacotherapy. Published electronically on 7 July 2009; DOI 10.134/aph.1M212.
23. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2009;32:650-7.
24. List JF, Woo V, Morales E, Tang Q, Fiedorek FT. Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatmentnaïve patients with type 2 diabetes [abstract]. Diabetologia 2008;51(Suppl. 1):S22-S23.
25. Bristol-Myers Squibb, AstraZeneca. A Phase III study of BMS-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled with diet and exercise [artículo online]. http://clinicaltrials.gov/show/NCT00528372 (NLM Identifier: NCT00528372).
26. Bristol-Myers Squibb, AstraZeneca. Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients [articulo online]. http://clinicaltrials.gov/show/NCT00660907 (NLM Identifier: NCT00660907).
27. AstraZeneca, Bristol-Myers Squibb. Efficacy and safety of dapagliflozin in combination with glimepiride (a sulphonylurea) in type 2 diabetes patients [artículo online]. http://clinicaltrials.gov/show/NCT00680745 (NLM Identifier: NCT00680745).
28. Bristol-Myers Squibb, AstraZeneca. Add-on to thiazolidinedione (TZD) failures [artículo online]. http://clinicaltrials.gov/show/NCT00683878 (NLM Identifier: NCT00683878).
29. AstraZeneca, Bristol-Myers Squibb. Efficacy and safety of dapagliflozin, added to therapy of patients with type 2 diabetes with inadequate glycemic control on insulin [artículo online]. http://clinicaltrials.gov/show/NCT00673231 (NLM Identifier: NCT00673231).